Biomarin Pharmaceuticals (BMRN) Stock Price, Quote & News

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 506 6700

Website: www.biomarin.com

Address:

770 Lindaro Street, San Rafael, United States

willwebb Jun. 16 at 6:31 PM

$BMRN

0 · Reply

AtotheZ Jun. 16 at 4:35 PM

$SRPT I remember the $BMRN battle days… I’m assuming things didn’t go as planned? That’s a huge drop in 3 months.

0 · Reply

TPTradingCo Jun. 12 at 9:07 PM

$BMRN Yahoo Finance has this up 340% all time. Why the huge difference with Stocktwits’ all time? And…getting ready to run…

0 · Reply

NancyPelosi____insider Jun. 12 at 1:37 PM

$CRDL $RGC $NVDA $SMMT $BMRN

0 · Reply

PaulVoice Jun. 10 at 5:01 PM

$BMRN low 60sh possible within the next days

0 · Reply

svk33 Jun. 9 at 3:32 PM

$BMRN Nice V today. Broke out of channel but more hurdles ahead. Need XLV to breakout 134.5, recapture 136 and were off to the races. Take your scalps bears. No sweating here.

0 · Reply

CallingStorms Jun. 9 at 2:38 AM

$BMRN this is the stock that makes you think you bought at the bottom

0 · Reply

jewell69 Jun. 6 at 4:28 PM

took profits in $OCUL and $BMRN (living in luxury on the pain and suffering of others )

0 · Reply

scienceleads Jun. 6 at 3:13 PM

$BMRN nothing but positive news for the last year.

0 · Reply

PaulVoice Jun. 6 at 1:54 PM

$BMRN gets some love today and breaking out the wedge

0 · Reply

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

INZY

May 16, 2025, 7:30 AM EDT - 4 weeks ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

INZY

May 12, 2025, 9:05 AM EDT - 5 weeks ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 1, 2025, 7:25 PM EDT - 6 weeks ago

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 6 weeks ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

Apr 17, 2025, 9:00 AM EDT - 2 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

Apr 3, 2025, 3:37 PM EDT - 2 months ago

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

Apr 2, 2025, 9:00 AM EDT - 2 months ago

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

Mar 20, 2025, 9:00 AM EDT - 3 months ago

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Feb 25, 2025, 9:00 AM EST - 3 months ago

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

Feb 24, 2025, 4:05 PM EST - 4 months ago

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Feb 20, 2025, 9:39 AM EST - 4 months ago

Why Is BioMarin Stock Trading Higher On Thursday?

Feb 19, 2025, 8:08 PM EST - 4 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 4:05 PM EST - 4 months ago

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

Feb 5, 2025, 9:00 AM EST - 4 months ago

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Jan 23, 2025, 10:42 AM EST - 5 months ago

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Jan 13, 2025, 12:00 PM EST - 5 months ago

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Jan 6, 2025, 8:30 AM EST - 5 months ago

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Nov 21, 2024, 3:00 PM EST - 7 months ago

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Nov 16, 2024, 10:45 AM EST - 7 months ago

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

Nov 6, 2024, 8:00 AM EST - 7 months ago

BioMarin to Participate in Three Upcoming Investor Conferences

Oct 29, 2024, 8:26 PM EDT - 8 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:03 PM EDT - 8 months ago

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

Oct 16, 2024, 8:30 AM EDT - 8 months ago

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

Oct 8, 2024, 2:42 PM EDT - 8 months ago

3 Oversold Stocks with Big RSI Rebound Potential

ELV HUM

Sep 25, 2024, 3:50 PM EDT - 9 months ago

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Sep 18, 2024, 8:00 AM EDT - 9 months ago

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Sep 17, 2024, 5:15 PM EDT - 9 months ago

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Sep 4, 2024, 1:00 PM EDT - 10 months ago

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Sep 4, 2024, 7:30 AM EDT - 10 months ago

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

Aug 29, 2024, 8:00 AM EDT - 10 months ago

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

Aug 28, 2024, 5:32 PM EDT - 10 months ago

BioMarin to reduce global workforce by about 225 employees

Aug 21, 2024, 4:21 PM EDT - 10 months ago

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Aug 21, 2024, 8:30 AM EDT - 10 months ago

BioMarin Announces New R&D and Business Development Leadership

Aug 19, 2024, 9:00 AM EDT - 10 months ago

BioMarin to Host 2024 Investor Day on September 4th in New York

Aug 6, 2024, 3:06 PM EDT - 11 months ago

Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance

Aug 5, 2024, 9:35 PM EDT - 11 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:03 PM EDT - 11 months ago

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

Aug 5, 2024, 4:01 PM EDT - 11 months ago

BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy

Jul 24, 2024, 4:05 PM EDT - 11 months ago

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

Jul 23, 2024, 8:00 AM EDT - 11 months ago

BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET

Jun 17, 2024, 8:30 AM EDT - 1 year ago

BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health

Jun 7, 2024, 9:00 AM EDT - 1 year ago

BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

May 4, 2024, 4:00 PM EDT - 1 year ago

New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting

Apr 24, 2024, 8:50 PM EDT - 1 year ago

BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 4:03 PM EDT - 1 year ago

BioMarin Reports Record Financial Results for the First Quarter 2024

Apr 10, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

Mar 12, 2024, 8:30 AM EDT - 1 year ago

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Mar 7, 2024, 8:30 AM EST - 1 year ago

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

willwebb Jun. 16 at 6:31 PM

$BMRN

0 · Reply

AtotheZ Jun. 16 at 4:35 PM

$SRPT I remember the $BMRN battle days… I’m assuming things didn’t go as planned? That’s a huge drop in 3 months.

0 · Reply

TPTradingCo Jun. 12 at 9:07 PM

$BMRN Yahoo Finance has this up 340% all time. Why the huge difference with Stocktwits’ all time? And…getting ready to run…

0 · Reply

NancyPelosi____insider Jun. 12 at 1:37 PM

$CRDL $RGC $NVDA $SMMT $BMRN

0 · Reply

PaulVoice Jun. 10 at 5:01 PM

$BMRN low 60sh possible within the next days

0 · Reply

svk33 Jun. 9 at 3:32 PM

$BMRN Nice V today. Broke out of channel but more hurdles ahead. Need XLV to breakout 134.5, recapture 136 and were off to the races. Take your scalps bears. No sweating here.

0 · Reply

CallingStorms Jun. 9 at 2:38 AM

$BMRN this is the stock that makes you think you bought at the bottom

0 · Reply

jewell69 Jun. 6 at 4:28 PM

took profits in $OCUL and $BMRN (living in luxury on the pain and suffering of others )

0 · Reply

scienceleads Jun. 6 at 3:13 PM

$BMRN nothing but positive news for the last year.

0 · Reply

PaulVoice Jun. 6 at 1:54 PM

$BMRN gets some love today and breaking out the wedge

0 · Reply

henkka123 Jun. 5 at 6:38 PM

$BMRN added a position here, I like it at these levels as markets are so high overall

0 · Reply

jewell69 Jun. 5 at 2:12 AM

more recent $BMRN trades, still very expensive in September 09/26/2024 Sell Trade Details BMRN BIOMARIN PHARMACEUTICAL 44 $70.055 $0.10 $3,082.32 09/26/2024 Buy Trade Details BMRN BIOMARIN PHARMACEUTICAL 44 $69.8597 -$3,073.83 Page Total: $8.49 profit. 6/4 close 56.11 wow

0 · Reply

jewell69 Jun. 5 at 2:07 AM

$BMRN BioMarin Pharmaceutical (BMRN) In a report released today, Gena Wang from Barclays maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $86.00. The company’s shares closed last Friday 5/9 at $58.86. 6/4 wednesday close 56.11 According to TipRanks.com, Wang is a 3-star analyst with an average return of 2.3% and a 39.3% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, 4D Molecular Therapeutics, and Vertex Pharmaceuticals. i traded in in early 2024 in 80s !!! 03/19/2024 Sell Trade Details BMRN TDA TRAN - Sold ...100 (BMRN) @84.9000 100 $84.90 $0.09 $8,489.91 03/13/2024 Buy Trade Details BMRN TDA TRAN - Bought ...100 (BMRN) @84.7000 100 $84.70 -$8,470.00 Page Total: $19.91 profit !!

0 · Reply

sanewalt Jun. 4 at 7:33 PM

$BMRN enjoy Hit my loss

0 · Reply

CDMO Jun. 3 at 6:29 PM

$BMRN dead money

0 · Reply

maddy1819 Jun. 3 at 2:13 PM

$IMNN Shocking results of IMNN Phase 2 cancer. IMNN about to squeeze https://www.gurufocus.com/news/2904431/imnn-promising-phase-2-results-in-ovarian-cancer-treatment-imnn-stock-news $BMGL $NVNI $BMRN $BGLC

0 · Reply

QuantumToZERO Jun. 3 at 2:12 AM

$BMRN Jan 16th 70 calls are a solid lotto 50$ strike price for basic leverage is good though

0 · Reply

QuantumToZERO Jun. 2 at 3:25 AM

$BMRN one of the best shtocks

0 · Reply

shoagh12 May. 27 at 3:09 PM

$BMRN

0 · Reply

SannieVerraderlijk May. 21 at 4:48 PM

$BMRN Starter on this cash machine

1 · Reply

HoosierTrades87 May. 21 at 5:15 AM

$BMRN has me intrigued - gotta love the market’s reaction to a company just off of Lows, that then announces an acquisition- looks like some traders agree. the only thing that has me leary is administration’s recent vendetta with drug pricing. Alerts/ Buying in the $55-$57 range

0 · Reply

SissyBoy May. 20 at 1:56 PM

$BMRN ripping off $INZY and they know it .

0 · Reply

Market Cap	10.78B
Revenue (ttm)	2.85B
Net Income (ttm)	426.86M
EPS (ttm)	N/A
PE Ratio	17.84
Forward PE	16.46
Profit Margin	14.96%
Debt to Equity Ratio	0.00

Volume	1,574,600
Avg Vol	2,128,198
Day's Range	N/A - N/A
Shares Out	191.78M
Stochastic %K	36%
Beta	0.19
Analysts	Strong Sell
Price Target	$96.81